Biotechnology company focusing on developing diagnostics and psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders Nova Mentis Life Sciences Corp. (CSE: NOVA) (OTCQB: NMLSF) says that it has expanded its psilocybin research and development program targeting obesity and diabetes.
Recently, the company concluded three preclinical psilocybin treatments of rats with symptoms of autism spectrum disorder (ASD). Apart from amelioration of anxiety and cognition issues in the ASD rats, Nova’s collaborative partners also uncovered extra significant findings related to the inflammatory cytokines and chemokines including their response to certain psilocybin dosing.
These thrilling unexpected findings strongly indicate that the proprietary psilocybin formulation by nova has the potential application to treat obesity as well as ‘diabesity’, a diabetes related obesity.
“NOVA’s technology has shown that its proprietary compound, psilocybin, can influence levels of inflammatory chemokines/cytokines that transmit physiologic messages with the potential to influence responses within the serotonergic system. A diagnostic mRNA genetic inflammatory panel is being developed with the assistance of Thermo Fisher Scientific and this panel will be studied in ASD individuals in an upcoming IRB approved observational clinical study,” said Nova’s chairman of scientific advisory board, Dr. Marvin S. Hausman.